Antiviral; Arenavirus envelope glycoprotein

LHF-535是一种小分子病毒进入抑制剂，针对沙粒病毒包膜糖蛋白（GP）。LHF-535对多种出血热沙粒病毒表现出强大的抗病毒活性。 LHF-535 抑制 Lassa GP 假型慢病毒，IC50 为 0.1-0.3 nM[2]。

LHF-535（3、10 或 30 mg/kg；口服；每日；14 天）显着降低血浆、脾脏和肝脏中的病毒滴度，同时保护小鼠免受致命的塔卡里布病毒攻击。延迟 LHF-535 的第一剂（感染后 1、2 或 3 天注射 LHF-535（10 mg/kg）也会导致存活率增加，这表明 LHF-535 作为小鼠暴露后治疗剂的有效性[2]。

Junín病毒产量减少测定法[2] 进行病毒产量降低（VYR）实验，以确定Junín-Romero野生型和疫苗株对LHF-535的敏感性。在感染前，将不同浓度的LHF-535添加到含有70-80%融合Vero细胞的测试孔中，感染复数（MOI）约为0.002。培养板培养3天，此时将感染病毒的培养板冷冻和解冻，并收集培养上清液用于感染病毒的终点滴定。将样品接种在Vero细胞上，并在感染后第10天测量视觉细胞病变效应。LHF-535针对Candid#1和Romero菌株进行一式三份的测试。接种疫苗的人员在BSL-3+实验室对Junín病毒的致病性Romero株进行了研究。

Tacaribe病毒抗病毒试验[2]
接种在96孔板中的Vero细胞（每孔5000个细胞）在DMSO中加入一式三份的系列化合物稀释液后，以0.1的MOI感染Tacaribe病毒。3天后，从细胞裂解物（Promega SV 96总RNA分离系统）中提取RNA，通过qRT-PCR和比较CT方法评估Tacaribe病毒的RNA[40]。简言之，提取的RNA用于用高容量RNA-to-cDNA试剂盒（Thermo Fisher Scientific）产生cDNA。对于基于TaqMan的qPCR，使用TaqMan-Fast Advanced Master Mix（Thermo Fisher Scientific）以及引物和双重标记的TaqMan-探针组（靶向GP的约100个核苷酸区域（nt 809–912））对cDNA进行反应。使用赛默飞世尔科学公司的18S rRNA（VIC/MGB探针）作为内部控制。

Tacaribe virus in vivo model[2]
AG129 mice are IFN-α/β and–γ receptor-deficient mice. They were a kind gift from Michael Diamond (Washington University in St. Louis). For Tacaribe virus studies, we used mice that were sex- and age-matched (6–8 weeks old). All animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) and were conducted at Kineta in a BSL-2 facility. Experimental groups were sized (as specified in the figure legends) to allow for statistical analysis, and all animals were included in the analysis. All animal experiments were conducted in a non-blinded fashion. For the LHF-535 dose titration study, mice were sorted into survival and titer arms and challenged by intraperitoneal (i.p.) injection with 200 PFU of Tacaribe virus. In the survival arm, mice were dosed orally with LHF-535 at 3, 10, or 30 mg/kg/day or with vehicle alone for 14 days with the first dose 30 min prior to infection. Micronized LHF-535 was suspended in 0.5% Methocel E15 and 1% Tween 80. The mice were observed for signs of morbidity and mortality. For the titer arm, mice were sacrificed at 7 days post-challenge; plasma, liver, and spleen samples were collected for assaying virus titers. For the delayed treatment studies, AG129 mice were split into five groups with each receiving LHF-535 30 min prior, and 24, 48, and 72 h post infection along with a vehicle control group. All mice were challenged by i.p. injection with 200 PFU of Tacaribe virus and dosing ceased 14 days post-challenge. The mice were observed for signs of morbidity and mortality and were humanely removed from study if there were clinical observations of inactivity, labored breathing, or excessive weight loss (≥20%). For the pathogenesis studies (LD50 determination), AG129 mice were infected with wild-type or mutant Tacaribe virus via i.p. injection using 10-fold serial dilutions of virus. The Reed-Muench method was used for LD50 calculations

[1]. Antiviral drugs for treatment of arenavirus infection. WO2013123215A2.

C27H28N2O2

412.52

412.22

C, 78.61; H, 6.84; N, 6.79; O, 7.76

LHF-535;1450929-77-7

Typically exists as light yellow to yellow solids at room temperature

5.8

47.3Ų

DBNZTRPIBJSUIX-WAYWQWQTSA-N

InChI=1S/C27H28N2O2/c1-19(2)31-24-14-12-23(13-15-24)29-18-28-25-17-21(9-16-26(25)29)6-5-20-7-10-22(11-8-20)27(3,4)30/h5-19,30H,1-4H3/b6-5-

(E)-2-(4-(2-(1-(4-Isopropoxyphenyl)-1H-benzo[d]imidazol-5-yl)vinyl)phenyl)propan-2-ol

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

DMSO :~60 mg/mL (~145.45 mM)

配方 1 中的溶解度: ≥ 2.5 mg/mL (6.06 mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将100 μL 25.0 mg/mL 澄清 DMSO 储备液加入900 μL 玉米油中，混合均匀。

---

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。